Alex Biese

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

A phase 1 clinical trial is open for enrollment to patients with high-grade neuroendocrine tumors.

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

The FDA has approved Opdivo with Yervoy for the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma.

The FDA has approved Jobevne, a biosimilar to Avastin, for IV use in a number of cancer types.

Vitrakvi, first granted accelerated approval in 2018, has received full approval from the FDA.

CT-95 is being developed for cancers including pancreatic, ovarian and mesothelioma and other solid tumors.

Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.

The American Heart Association has released a statement detailing cardiometabolic considerations for survivors of childhood cancer.

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ovarian cancer has been launched.

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on to final analysis.

A new comprehensive hereditary cancer solution offers genetic counseling and multigene panels to enhance early detection of disease's like brain cancer.

Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to COMPANION-002 study results.

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.

A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or liposarcoma (LPS).

Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.

Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.

A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient Multiple Myeloma Summit.

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.